Literature DB >> 9843870

PGE2, via EP3 receptors, regulates brain nitric oxide synthase in the perinatal period.

I Dumont1, K G Peri, P Hardy, X Hou, A K Martinez-Bermudez, S Molotchnikoff, D R Varma, S Chemtob.   

Abstract

We tested the hypothesis that high prostaglandin levels during the perinatal period might regulate brain nitric oxide synthase (nNOS) expression. nNOS and cyclooxygenase (COX)-2 mRNAs were higher in brain cortex and the periventricular area of newborn rats and pigs compared with adult brain. Nitric oxide synthase activity was also 2. 5- to 4-fold higher in newborn than in adult brain. Administration of nonselective COX inhibitor ibuprofen or COX-2 inhibitor nimesulide every 8 h for 24 h to newborn rats and pigs reduced prostaglandin levels and caused comparable reductions in nNOS mRNA, protein, and activity to levels of adults; COX inhibitor-induced changes were prevented by cotreatment with PGE2 analog, 16, 16-dimethyl-PGE2, and agonist for the EP3 receptor of PGE2, sulprostone, but not by PGI2 analog carbaprostacyclin, PGD2, EP1 receptor agonist 17-phenyl trinor-PGE2, and EP2 agonist butaprost. Concordant observations were made in vitro and revealed that nNOS expression (detected by NADPH diaphorase reactivity) mostly present in neurons of the deeper cortical layers was reduced by COX inhibitor, and this effect was prevented by EP3 agonist. In conclusion, high levels of PGE2 in neonatal brain contribute to the increased expression of nNOS by acting on EP3 receptors; this positive interaction between PGE2 and nNOS might be required physiologically for normal brain development.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9843870     DOI: 10.1152/ajpregu.1998.275.6.R1812

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

1.  Betamethasone effects on fetal sheep cerebral blood flow are not dependent on maturation of cerebrovascular system and pituitary-adrenal axis.

Authors:  Matthias Löhle; Thomas Müller; Carola Wicher; Marcus Roedel; Harald Schubert; Otto W Witte; Peter W Nathanielsz; Matthias Schwab
Journal:  J Physiol       Date:  2005-02-17       Impact factor: 5.182

2.  Nuclear localization of prostaglandin E2 receptors.

Authors:  M Bhattacharya; K G Peri; G Almazan; A Ribeiro-da-Silva; H Shichi; Y Durocher; M Abramovitz; X Hou; D R Varma; S Chemtob
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics.

Authors:  Joshua C Neuman; Michelle E Kimple
Journal:  J Endocrinol Diabetes Obes       Date:  2013 Jul-Sep

4.  Nitric oxide synthase 1 and cyclooxygenase-2 enzymes are targets of muscarinic activation in normal and inflamed NIH3T3 cells.

Authors:  A J Español; N Goren; M L Ribeiro; María Elena Sales
Journal:  Inflamm Res       Date:  2009-10-13       Impact factor: 4.575

5.  Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo.

Authors:  Dejan Milatovic; Snjezana Zaja-Milatovic; Kathleen S Montine; Feng-Shiun Shie; Thomas J Montine
Journal:  J Neuroinflammation       Date:  2004-10-21       Impact factor: 8.322

Review 6.  Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes.

Authors:  Michelle E Kimple; Joshua C Neuman; Amelia K Linnemann; Patrick J Casey
Journal:  Exp Mol Med       Date:  2014-06-20       Impact factor: 8.718

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.